Build a "healthy China" and release the data analysis report of medical and health industry

Source: driven by vcsaas technology, Premier Li Keqiang of the State Council on August 3, 2017 said during a visit on April 19, 2017, "China has entered the ranks of middle-income countries, and the demand for medical health is growing However, the industry currently accounts for less than 5% of China's industry There is a big gap with developed countries, and the market potential is huge We should make the medical industry a pillar industry in China " According to the analysis report on the development prospect forecast and investment strategic planning of global health and medical big data industry issued by prospective industry research institute, the market scale of China's health industry has exceeded 4 trillion yuan, and the concept of "healthy China" has been promoted to the strategic position of priority development The outline clearly proposes that the total scale of health service industry will exceed 8 trillion yuan and 16 trillion yuan in 2020 and 2030 "Healthy China" strategy will become an important engine for the development of China's medical and health industry This report, jointly produced by Zhengzhong investment group and VC SaaS, hopes to provide some useful references for practitioners and investors engaged in the medical and health industry The report focuses on the whole network monitoring of 2239 pharmaceutical and health industry enterprises status quo of domestic listed pharmaceutical and health industry enterprises status quo of domestic listed pharmaceutical and health industry enterprises status quo of China's pharmaceutical and health online service industry classification map global medical and health industry segmentation enterprises and product distribution approval trend of China US New drugs development situation of Fosun Pharmaceutical Group VC SaaS has monitored the development data of 2239 global medical and health industry enterprises through public information, and analyzed the industry segmentation and listed leading enterprises through these data According to the data monitored by the whole network, at present, the number of Chinese medical and health industry enterprises in the global scope is relatively large, leading the global medical and health industry market together with the United States In China, the number of medical and health enterprises in Beijing is the largest, reaching 304, followed by Guangdong, Shanghai, Zhejiang and Jiangsu From this point of view, in China, the regional distribution of pharmaceutical and health industry enterprises is strong Besides Beijing, it is also mainly distributed in the Yangtze River Delta and Pearl River Delta From the perspective of financing rounds, the financing dynamic of global pharmaceutical health industry is relatively active, among which the number of financing events in round a financing and directional additional issuance is more than other rounds, accounting for 19.75% and 15.05% of the total number of financing events respectively In China, the more active investment institutions are shown in the figure above IDG capital has sold 26 times in the medical and health industry, followed by Junlian capital, with a total of 22 times of investment The pharmaceutical and health industry enterprises that turn their attention to domestic IPO have relative regional characteristics The number of IPO events is increasing, but it is also affected by regulatory policies and domestic financial market But on the whole, they are doing well As shown in the figure above, except for the closing of IPO window and slowing down of policies in 2013, the IPO of domestic pharmaceutical and health industry enterprises has reached a peak in recent years, especially in 2010, 2011 and 2015, the number of pharmaceutical and health industry IPO is the largest It is expected that this year, the number of IPOs of domestic pharmaceutical enterprises will break a record, reaching the highest ever Among the listed medical and health enterprises in China, the number of enterprises from Guangdong, Zhejiang and Jiangsu is the largest It shows that China's medical and health industry has developed in full swing in the Pearl River Delta and Yangtze River Delta, and the leading listed enterprises are mainly concentrated in these areas In China, only 9.09% of the listed pharmaceutical enterprises are in the state of loss and the rest are in the state of profit At present, the enterprises queuing for IPO are still the most in Yangtze River Delta and Pearl River Delta In the competition of three kinds of devices, the competition between implant materials and artificial organs is more intense A total of 1299 enterprises have developed 7140 products for market selection In the development competition of class II devices, the market competition of clinical test and analysis instruments is relatively fierce, which shows that the research and clinical application of medical test and detection are very active in the world A total of 2454 enterprises have developed 12686 products for selection With the continuous change of global environment, the pathogenic environment and disease change more and more There is a great demand for the detection of antigen, antibody and nucleic acid of the pathogen 396 enterprises have developed 5974 kinds of products for practitioners to choose from There is a large demand for reagents for protein detection among class II in vitro diagnostic reagents, and 8533 products are available for market selection Because most of the advanced diseases belong to infectious diseases, anti infectious drugs are the most in the chemical drugs Up to now, 42675 kinds of anti infective drugs have been put into clinical application Based on the principle of traditional Chinese medicine and the pharmacology of traditional Chinese medicine, the most of them are used in internal medicine Precision medicine is a rising star in the medical industry, and the services provided by various enterprises are different, among which there are more enterprises focusing on PCR There are 816 China's well-known enterprises in the precision industry include Huada gene, Daan gene, Beirui Hekang, Kehua biology, etc All of the four companies have been listed successfully in China's A-share market by means of backdoor IPO According to the data of the above industry segments, it can be seen that chemical drugs, Chinese patent medicines and other drugs used for clinical treatment are highly competitive and mature The market scale of precision medical industry still has a large development space, and the development of in vitro diagnostic reagent industry also needs a complete ecological development With the continuous innovation of technology, the medical device industry will be updated in the near future, and practitioners will have the opportunity to rely on technology to benefit patients and medical personnel According to the real-time test data, we can see the comparison between China and the United States in the trend of new drug approval Due to the strict drug control in China, the trend of drug approval lags behind the United States So in the clinical treatment of drugs, there are not as many drugs to choose as in the United States If the Chinese government departments and medical management departments have some liberalization in drug approval, the medical and health industry in China will also have an explosive growth point, and there will be more drugs for patients to choose.